CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 5, 2005--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a realignment designed to drive growth by creating an even stronger linkage between its product development cycle and customer base. Effective January 1, 2006, the company will create three new divisions under the traditional BioDiscovery and BioProduction business segments: Life Sciences, Bio-Production Systems and Services, and Enabling Technologies. Each of the divisions will have dedicated manufacturing, research and development, and marketing functions.
